Roche Investor Update: Roche presents new, fully automated lab solution at Europe’s largest diagnostics conference Mittwoch, 22. Mai 2013 - 07:08
Roche presents new, fully automated lab solution at Europe’s largest diagnostics conference System improves efficiency and speed of blood sample testing in medical labs
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today at the IFCC Euromedlab in Milan, Italy that it will soon introduce the cobas 8100 automated workflow series, a new solution for use in diagnostic laboratories. cobas 8100 automates numerous routine diagnostic laboratory tasks, while maximising patient safety. Using intelligent robotics, the new system automatically prepares blood samples for immediate testing and post-analytical processing. cobas 8100 improves a laboratory’s testing efficiency and enables healthcare professionals to make fast and reliable treatment decisions. Market availability is expected in autumn this year.
Increasing cost pressures in healthcare are forcing laboratories to increase efficiency and reduce expenses. Lab automation through integrated robotics and IT solutions is therefore becoming critical as a way of simplifying operations, reducing manual handling, and at the same time maximising patient safety.
“As a leading supplier of laboratory instruments, tests, automated workflow and data management solutions, Roche is supporting effective medical decision-making and contributing to higher efficiency in the medical laboratory,” said Roland Diggelmann, Chief Operating Officer of Roche Diagnostics. “The new cobas solution will improve the way many laboratories operate. Total lab automation not only lowers costs and increases productivity, it also minimises the risk of sample mix-ups or contamination through manual handling by lab personnel. With short and predictable turn-around times, it helps physicians to make timely treatment decisions for patients.”
cobas 8100 features an innovative and intelligent routing and prioritisation system, providing more than twice the processing speed of Roche’s previous system. Healthcare professionals benefit from on-time, high quality diagnostic results for routine and emergency tests, even at laboratory workload peaks. cobas 8100 can easily be added onto existing cobas analysers, and its flexible, modular design allows labs to grow over time as demand increases. The recent trend to lab consolidation in the diagnostics industry has increased the need for automated, high throughput solutions that manage workflow across sites. cobas 8100 combined with cobas IT solutions gives labs full and transparent control over the entire process in a complex environment.
Combined with Roche’s sample archiving solutions, the cobas 8100 provides unprecedented flexibility, simplifying and speeding up routines for archiving and on-demand retrieval of blood samples. This allows for full automation and traceability from blood sample entry to result reporting and archiving.
About Roche Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, infectious diseases, inflammation, metabolism and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2012 Roche had over 82,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 45.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.
With best regards,
Roche Investor Relations
Dr. Karl Mahler Phone: +41 61 68-78503 e-mail: karl.mahler@roche.com
Dr. Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com
Luís Correia Ph.D. Phone: +41 61 68-75284 e-mail: luis.correia@roche.com
Tamer Farhan Ph.D. Phone: +41 61 68-82552 e-mail: tamer.farhan@roche.com
Dr. Nina Mojas Phone: +41 61 68-71300 e-mail: nina.mojas@roche.com
Elhan Webb, CFA Phone: +41 61 68-89630 e-mail: elhan.webb@roche.com
Investor Relations North America
Thomas Kudsk Larsen Phone: +1 650 467 2016 e-mail: larsen.thomas@gene.com
Nina Goworek Phone: +1 650 467 8737 e-mail: goworek.nina@gene.com
Ekaterine Kortkhonjia Ph.D. Phone: +1 650 467 5873 e-mail: kortkhonjia.ekaterine@gene.com